Celularity Inc. (NASDAQ:CELU – Get Free Report) was the target of a large drop in short interest in April. As of April 15th, there was short interest totalling 393,100 shares, a drop of 5.5% from the March 31st total of 415,800 shares. Based on an average daily trading volume, of 98,300 shares, the short-interest ratio is presently 4.0 days. Currently, 3.7% of the company’s stock are sold short.
Institutional Trading of Celularity
An institutional investor recently raised its position in Celularity stock. IPG Investment Advisors LLC grew its position in Celularity Inc. (NASDAQ:CELU – Free Report) by 97.9% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 171,695 shares of the company’s stock after buying an additional 84,928 shares during the period. IPG Investment Advisors LLC owned 0.09% of Celularity worth $38,000 at the end of the most recent quarter. 19.02% of the stock is currently owned by institutional investors and hedge funds.
Celularity Stock Down 0.3 %
Shares of NASDAQ:CELU traded down $0.01 during trading on Tuesday, reaching $2.99. The stock had a trading volume of 6,329 shares, compared to its average volume of 215,408. Celularity has a one year low of $1.59 and a one year high of $8.90. The firm’s 50-day simple moving average is $4.62 and its 200 day simple moving average is $3.33.
Celularity Company Profile
Celularity Inc, a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease.
Read More
- Five stocks we like better than Celularity
- Breakout Stocks: What They Are and How to Identify Them
- NXP Semiconductors Will Set a New High Soon: $300 in Sight
- What does consumer price index measure?
- Hilton Demonstrates Asset Light is Right for Investors
- Upcoming IPO Stock Lockup Period, Explained
- Boston Scientific Bucks the Medtech Slow Down and Raises Outlook
Receive News & Ratings for Celularity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celularity and related companies with MarketBeat.com's FREE daily email newsletter.
